PSMA4: A Key Regulator of Myeloma Cell Growth and More (G5685)

Target Name: PSMA4

NCBI ID: G5685

PSMA4

PSMA4: A Key Regulator of Myeloma Cell Growth and More

PSMA4 (Proteasome-Mediated Splitting of Myeloma Samples) is a protein that is expressed in multiple myeloma samples, and it is involved in the regulation of the self-renewal and differentiation of myeloma cells. Myeloma is a type of cancer that affects the bone marrow, and it is characterized by the uncontrolled proliferation of myeloma cells.

PSMA4 is a key regulator of myeloma cell growth and self-renewal. It is expressed in a variety of myeloma samples, including primary cultures, blood samples, and bone marrow samples. PSMA4 has been shown to play a role in the regulation of myeloma cell division, cell survival, and angiogenesis.

PSMA4 is also involved in the regulation of myeloma cell interactions with other immune cells and tissues. Myeloma cells have been shown to be able to migrate and integrate into the surrounding tissue, which can lead to the formation of tumors. PSMA4 has been shown to play a role in the regulation of these processes, as well as in the development of resistance to chemotherapy.

PSMA4 is also a potential drug target for myeloma. Myeloma is a difficult-to-treat cancer, and there is a need for new treatments that can effectively target myeloma cells. PSMA4 is an attractive target for this purpose, as it is involved in the regulation of myeloma cell growth and self-renewal, and it is also involved in the regulation of myeloma cell interactions with other immune cells and tissues.

In addition to its potential as a drug target, PSMA4 is also a potential biomarker for myeloma. The diagnosis of myeloma is often based on the presence of certain markers in the blood, such as MCL-1 and BCL-2. PSMA4 has been shown to be expressed in the blood samples of myeloma patients, and it has been suggested as a potential biomarker for myeloma.

PSMA4 is also involved in the regulation of myeloma cell apoptosis, which is a process by which myeloma cells die when they have reached a certain level of proliferation. Myeloma cells have been shown to have a higher rate of apoptosis than healthy myeloma cells, which may be a potential mechanism for their anti-tumor effects. PSMA4 has been shown to play a role in the regulation of myeloma cell apoptosis, and it may be a useful target for the development of new treatments for myeloma.

In conclusion, PSMA4 is a protein that is expressed in multiple myeloma samples and is involved in the regulation of myeloma cell growth, self-renewal, and interactions with other immune cells and tissues. PSMA4 is also a potential drug target and biomarker for myeloma, and further research is needed to fully understand its role in these processes.

Protein Name: Proteasome 20S Subunit Alpha 4

Functions: Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)

The "PSMA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSMA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets